Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
John Inge, the Bishop of Worcester, says the death of his wife from cancer at the age of 51 has set him in opposition to the legislation.
A cool weekend ahead but looking dry for many with sunny spells.
Firefighters have warned residents in London that an ongoing blaze could spark the explosion of a gas cylinder.